DALLAS, Jan. 12, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biopharmaceutical company StemCell Inc. (Nasdaq:STEM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/STEM
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
StemCells Inc. (STEM) is engaged in the development and commercialization of cell-based therapies to restore or aid central nervous system and liver affected by disease. The Company's primary drug candidate, HuCNS-SC, is presently in Food and Drug Administration clinical trials for the treatment of neuronal ceroid lipofuscinosis in children.
In the report, the analyst notes:
"The Company's CNS Program includes HuCNS-SC, a product candidate presently in Food and Drug Administration (FDA) trials for the treatment of two infantile neuronal ceroid lipofuscinosis (NCL) disorders (commonly know as Batten disease). In January 2009, the Company reported that phase I FDA clinical trials of HuCNS-SC showed that donor cells survived, engrafted well, and were tolerated by patients in a six-patient study.
"In November, the Company completed a sale to institutional investors of 10 million shares of common stock and warrants to purchase an additional 4 million shares of common stock. The Company said in a news release that it raised $12.5 million in gross proceeds, banking $11.9 million in net proceeds after expenses. The cash will be used for general corporate purposes, including working capital, product development and capital expenditures."
To read the entire report visit: http://www.beaconequity.com/i/STEM
See what investors are saying about these stocks at penny stock forum.
BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.